A randomized phase II study of pivanex and docetaxel compared to docetaxel monotherapy in patients with previously treated advanced NSCLC

被引：1
|
作者：
Raghunadharao, D
Koralewski, P
Serwatowski, P
Gruszfeld, A
Lakshmaiah, K
Szczesna, A
Savin, M
Yen, K
Bhatnagar, A
Green, M
机构：
[1] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[2] Szpital Specjalistyczny Rydygiera, Krakow, Poland
[3] Szpital Specjalistyczny Alfreda, Szczecin, Poland
[4] Warminsko Mazurskie Ctr Onkol, Olsztyn, Poland
[5] Kidwai Mem Inst Oncol, Bangalore, Karnataka, India
[6] Mazawieckie Ctr Leczenia, Otwock, Poland
[7] Texas Canc Ctr Med City, Dallas, TX USA
[8] Tita Pharmaceut Inc, San Francisco, CA USA
[9] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81053-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [31] Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
    Sparano, Joseph A.
    Makhson, Anatoly N.
    Semiglazov, Vladimir F.
    Tjulandin, Sergei A.
    Balashova, Olga I.
    Bondarenko, Igor N.
    Bogdanova, Natalia V.
    Manikhas, George M.
    Oliynychenko, Gennadiy P.
    Chatikhine, Valery A.
    Zhuang, Sen H.
    Xiu, Liang
    Yuan, Zhilong
    Rackoff, Wayne R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4522 - 4529
  • [32] A Phase 1 Trial of Dose Escalated BGB324 in Combination with Docetaxel for Previously Treated Advanced NSCLC
    Gerber, D.
    Levin, P.
    Fattah, F.
    Brekken, R.
    Currykosky, P.
    Padro, J.
    Yule, M.
    Wnuk-Lipinska, K.
    Naevdal, E.
    Boniecka, A.
    Gausdal, G.
    Lorens, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2086 - S2086
  • [33] Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
    Yoneshima, Yasuto
    Morita, Satoshi
    Ando, Masahiko
    Nakamura, Atsushi
    Iwasawa, Shunichiro
    Yoshioka, Hiroshige
    Goto, Yasuhiro
    Takeshita, Masafumi
    Harada, Toshiyuki
    Hirano, Katsuya
    Oguri, Tetsuya
    Kondo, Masashi
    Miura, Satoru
    Hosomi, Yukio
    Kato, Terufumi
    Kubo, Toshio
    Kishimoto, Junji
    Yamamoto, Nobuyuki
    Nakanishi, Yoichi
    Okamoto, Isamu
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1523 - 1532
  • [34] Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
    Fanucchi, Michael P.
    Fossella, Frank V.
    Belt, Robert
    Natale, Ronald
    Fidias, Panos
    Carbone, David P.
    Govindan, Ramaswamy
    Raez, Luis E.
    Robert, Francisco
    Ribeiro, Maria
    Akerley, Wallace
    Kelly, Karen
    Limentani, Steven A.
    Crawford, Jeffrey
    Reimers, Hans-Joachim
    Axelrod, Rita
    Kashala, Oscar
    Sheng, Shihong
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) : 5025 - 5033
  • [35] Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
    Takayama, Koichi
    Sugawara, Shunichi
    Saijo, Yasuo
    Maemondo, Makoto
    Sato, Atsushi
    Takamori, Shinzo
    Harada, Taishi
    Sasada, Tetsuro
    Kakuma, Tatsuyuki
    Kishimoto, Junji
    Yamada, Akira
    Noguchi, Masanori
    Itoh, Kyogo
    Nakanishi, Yoichi
    JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [36] Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma
    Lee, Eun Mi
    Rha, Sun Young
    Lee, Jeeyun
    Park, Kyong Hwa
    Ahn, Jin-Hee
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (03) : 635 - 642
  • [37] Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma
    Eun Mi Lee
    Sun Young Rha
    Jeeyun Lee
    Kyong Hwa Park
    Jin-Hee Ahn
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 635 - 642
  • [38] A phase 2 study of talabostat/docetaxel in advanced NSCLC.
    Cunningham, C
    Richards, D
    Salgia, R
    Leonard, R
    Raju, R
    Berman, B
    Anthony, S
    Yang, ZJ
    Gregoire, L
    Haltom, E
    Uprichard, MJ
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9056S - 9057S
  • [39] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    R Petrioli
    A Pascucci
    R Conca
    G Chiriacò
    E Francini
    G Bargagli
    A I Fiaschi
    A Manganelli
    G De Rubertis
    G Barbanti
    R Ponchietti
    G Francini
    British Journal of Cancer, 2011, 104 : 613 - 619
  • [40] Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
    Petrioli, R.
    Pascucci, A.
    Conca, R.
    Chiriaco, G.
    Francini, E.
    Bargagli, G.
    Fiaschi, A. I.
    Manganelli, A.
    De Rubertis, G.
    Barbanti, G.
    Ponchietti, R.
    Francini, G.
    BRITISH JOURNAL OF CANCER, 2011, 104 (04) : 613 - 619
12345